to withdraw from this protocol at any time. No patient will be accepted for treatment 
without such a document signed by him or his legal guardian. 
See attached document of informed consent in section . 
Patients may be asked to volunteer for other appended or ancillary protocols which 
investigate other questions such as issues of supportive care, the use of hematopoietic 
growth factors, management of infectious diseases and/or their prophylaxis, and 
pharmacokinetic studies. Such protocols will not be implemented without the review 
and approval of the Clinical Trials Committee. In circumstances where such 
protocols are approved, a separate informed consent document, consistent with the 
above guidelines, will be obtained. A patients participation in such ancillary protocols 
is voluntary and will be effect his/her participation or eligibility for the primary 
question of high-dose chemotherapy and ABMT. 
[ 730 ] 
Recombinant DNA Research, Volume 14 
